Torrent Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on July 28, 2025. - Financial Results
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts more than Nifty 100 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Torrent Pharma's Board approved Q1 FY26 results on July 28, 2025. Consolidated revenue rose 11% YoY to Rs. 3,178 crores, with operating EBITDA up 14% at Rs. 1,032 crores (margin ~32.5%). Net profit grew 20% YoY to Rs. 548 crores, and EPS stood at Rs. 16.19 (standalone EPS Rs. 16.28). India revenue grew 11% to Rs. 1,811 crores, US was up 19% to Rs. 308 crores, Brazil rose 11%, and Germany grew 9%. The auditor (BSR & Co. LLP) issued an unqualified opinion with no qualifications. The Board also approved issuance of unsecured/secured redeemable NCDs/bonds via private placement. The filing disclosed a major acquisition: a definitive agreement to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals for ~Rs. 11,917 crores (46.39% stake at Rs. 1,600/share), plus a mandatory open offer and a proposed merger.
Strong Q1 with 20% PAT growth reflects healthy operating momentum, likely positive for the stock. However, the ~Rs. 11,917 crore JB Pharma acquisition is a significant capital outlay that will raise leverage and execution risk; investors should monitor deal approvals, financing, and post-merger integration.